Psilocin | Jotup

ACS Laboratory Expands Testing Scope and Introduces Amanita Mushroom Testing Panels for Product Safety and Compliance

Retrieved on:

Wednesday, August 16, 2023

Psilocybin, United States Department of the Army, Powder, BOCA, Research, COA, Capsule, DEA, ACS, Cannabis, Psilocin, Safety, Amanita, Pharmaceutical industry, Mushroom

BOCA RATON, Fla., Aug. 16, 2023 /PRNewswire/ -- ACS Laboratory, the largest hemp and cannabis testing facility in the Eastern U.S., launched a comprehensive Amanita mushroom testing program.

Key Points:

BOCA RATON, Fla., Aug. 16, 2023 /PRNewswire/ -- ACS Laboratory, the largest hemp and cannabis testing facility in the Eastern U.S., launched a comprehensive Amanita mushroom testing program.
In 2023, ACS Laboratory expanded its testing scope from cannabis and hemp to mushrooms and Kratom.
Having a DEA license enables ACS Laboratory to test psilocybin containing mushrooms as well as Amanita products for compliance.
ACS Laboratory tests Amanita mushrooms in various product types, including dried mushrooms, powders, chocolates, tinctures, gummies and capsules.

Mindset Pharma Presents Poster at Neuroscience 2022 Highlighting Preclinical Data on MSP-1014, its Psilocybin-like Lead Drug Candidate

Retrieved on:

Monday, November 14, 2022

Joseph Araujo, Chief Scientific Officer, Director of Mindset Pharma, presented the findings at Neuroscience 2022 hosted by the Society of Neuroscience (SfN) in a poster titled The Preclinical Safety, Behavioural and Pharmacokinetics Properties of MSP-1014, a Novel Prodrug of Psilocin .

Key Points:

Joseph Araujo, Chief Scientific Officer, Director of Mindset Pharma, presented the findings at Neuroscience 2022 hosted by the Society of Neuroscience (SfN) in a poster titled The Preclinical Safety, Behavioural and Pharmacokinetics Properties of MSP-1014, a Novel Prodrug of Psilocin .
Psilocybin is a dihydrogen phosphonate prodrug of psilocin, which is thought to mediate antidepressant effects primarily by activation of 5-HT2A receptor subtype.
MSP-1014 was also evaluated in a drug discrimination assay in which rats were trained to discriminate a psilocybin cue from saline.
Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs.

Open For Business: Optimi Completes First Grow of Psilocybin Mushrooms and Introduces Head of Cultivation

Retrieved on:

Wednesday, May 25, 2022

Psilocybin, Form, Company, Medicine, GMP, FDR, News, Patient, Science, EU, Health, FOR, Research, Metis, CSE, Genetics, Industry, Special access program, Sale, Drug development, Party, Psilocin, SAP, Cree, FRA, Phrase, GLOBE, Great Spirit, Spirit, Fungus, Fungiculture, Pharmaceutical industry, Risk management

It has been an amazing two-year journey getting to where we are today, said Bill Ciprick, Optimi CEO.

Key Points:

It has been an amazing two-year journey getting to where we are today, said Bill Ciprick, Optimi CEO.
Parties interested in purchasing Optimi psilocybin and functional products should send an email to [email protected] where a member of the sales team will respond within 24 hours.
Ciprick credits the Companys success on the hard work of Optimi Chief Science Officer, Justin Kirkland, and new Head of Cultivation, Todd Henderson.
Optimi Health is a homegrown, Canadian success story producing and supplying natural, EU-GMP grade psilocybin and functional mushrooms that focus on the health and wellness markets.

U.K. Member of Parliament Crispin Blunt To Inaugurate Psilocybin Cultivation Facility At Optimi Health Grand Opening

Retrieved on:

Thursday, May 19, 2022

Psilocybin, Headache, Company, Conservative Party, GMP, Â, FDR, Science, EU, Government, House, Health, FOR, Blunt, MP, Depression, Research, Rehabilitation, Reigate, CSE, Sale, Psilocin, Friends, Speech, Golden Joystick Awards, FRA, GLOBE, CEO, Fungus, Fungiculture, Pharmaceutical industry, BC, Prison

It is an honour for Optimi Health to welcome Crispin Blunt, MP, to our May 27 Grand Opening Ceremony, said Bill Ciprick, CEO of Optimi Health.

Key Points:

It is an honour for Optimi Health to welcome Crispin Blunt, MP, to our May 27 Grand Opening Ceremony, said Bill Ciprick, CEO of Optimi Health.
Optimis founders, advisory board, and executive team are pleased to host such an internationally recognizable figure in the ongoing dialogue around therapeutic psilocybin.
I am thrilled to be associated with some of the great work currently being undertaken by our friends in Canada, said Blunt.
Optimi Health is a homegrown, Canadian success story producing and supplying natural, EU-GMP grade psilocybin and functional mushrooms that focus on the health and wellness markets.

Optimi Health Acquires Extensive Catalog of Psychedelic and Functional Mushroom Genetics

Retrieved on:

Tuesday, May 17, 2022

Psilocybin, Catalog, Form, Company, GMP, FDR, News, Patient, Science, EU, Health, FOR, Â, Good manufacturing practice, Research, CSE, Genetics, Good, Sale, SAP, Psilocin, Acquisition, FRA, Drug discovery, Phrase, GLOBE, Fungus, Fungiculture, Fine chemical, Pharmaceutical industry, Risk management, BC

The Companys acquisition includes 24 psychedelic and nine functional strains, giving it one of the largest genetic banks in the sector.

Key Points:

The Companys acquisition includes 24 psychedelic and nine functional strains, giving it one of the largest genetic banks in the sector.
As a leading cultivator of natural EU-GMP psilocybin, Optimi will begin processing its genetics for supply to patients requesting natural product.
Optimi CEO Bill Ciprick expanded on the shared scientific and commercial advantages provided by the companys comprehensive knowledge of psilocybin genetics.
Optimi Health is a homegrown, Canadian success story producing and supplying natural, EU-GMP grade psilocybin and functional mushrooms that focus on the health and wellness markets.

Optimi Health Completes Expansion Of On-Site Analytical Laboratory

Retrieved on:

Wednesday, May 11, 2022

Psilocybin, EU, SAP, Psilocin, Special access program, FOR, GLOBE, FDR, Company, Form, Fungus, Patient, CSE, FDA, FRA, GMP, Compliance, Health, Phrase, Sale, Science, Health Canada, News, Good, Research, Fungiculture, Dietary supplement, Fine chemical, Risk management

(CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (Optimi or the Company), is pleased to announce that it has completed a planned expansion of the on-site analytical laboratory at its Princeton, British Columbia facility.

Key Points:

(CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (Optimi or the Company), is pleased to announce that it has completed a planned expansion of the on-site analytical laboratory at its Princeton, British Columbia facility.
Optimi Chief Science Officer, Justin Kirkland, will oversee the Companys analytical operations.
Optimi CEO Bill Ciprick says that the lab expansion is a critical component of the Companys planned revenue strategy.
Optimi Health is a homegrown, Canadian success story producing and supplying natural, EU-GMP grade psilocybin and functional mushrooms that focus on the health and wellness markets.

Optimi Health Applauds Health Canada’s Position on Drug Quality and Goods and Manufacturing Practices (GMP) for Psilocybin

Retrieved on:

Monday, May 9, 2022

Ciprick says the Notice published by Health Canadas Office of Legislative and Regulatory Affairs Controlled Substances Directorate was welcomed by Optimi, specifically around the importance of drug quality and Good Manufacturing Practices (GMP).

Key Points:

Ciprick says the Notice published by Health Canadas Office of Legislative and Regulatory Affairs Controlled Substances Directorate was welcomed by Optimi, specifically around the importance of drug quality and Good Manufacturing Practices (GMP).
While the Company is uniquely positioned to be a world leader in the cultivation and supply of natural, scalable, and accessible psilocybin, Ciprick believes Health Canadas message is one that benefits every industry supplier.
Over the last year, Optimi has embarked on a transformational journey that has seen our company become a world leader in the supply of natural, EU-GMP grade psilocybin and functional mushrooms.
Optimi Health is a homegrown, Canadian success story producing and supplying natural, EU-GMP grade psilocybin and functional mushrooms that focus on the health and wellness markets.

Optimi Health Granted Amendment To Controlled Substances Dealer’s Licence

Retrieved on:

Wednesday, May 4, 2022

VANCOUVER, British Columbia, May 04, 2022 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (Optimi or the Company), is pleased to announce that a requested Amendment to its Controlled Substances Dealers Licence has been granted by Health Canada, enabling it to further expand the capacity to produce natural, GMP psilocybin at its Princeton, British Columbia facility, as well as introducing a provision allowing the Company to extract psilocin for use in clinical trials.

Key Points:

VANCOUVER, British Columbia, May 04, 2022 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (Optimi or the Company), is pleased to announce that a requested Amendment to its Controlled Substances Dealers Licence has been granted by Health Canada, enabling it to further expand the capacity to produce natural, GMP psilocybin at its Princeton, British Columbia facility, as well as introducing a provision allowing the Company to extract psilocin for use in clinical trials.
Optimi Labs Inc. , a wholly owned subsidiary of Optimi Health, filed the amendment in March 2022 in order to ensure adequate supply for licensed companies undertaking molecular development research and Phase 2a and 2b clinical trials investigating the treatment of addictions and mental health conditions.
This approval from federal health authorities for an effective doubling of our growing potential is an important milestone in Optimis planned year of commercialization, said Optimi Health CEO Bill Ciprick.
Any forwardlooking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.

Optimi Health Opens Canada’s Largest GMP-Grade Licensed Psilocybin Cultivation Facility

Retrieved on:

Thursday, April 28, 2022

Committed to showcasing a world-class GMP-grade cultivation facility for mushroom enthusiasts, Optimi plans to livestream the event on Instagram for guests unable to attend.

Key Points:

Committed to showcasing a world-class GMP-grade cultivation facility for mushroom enthusiasts, Optimi plans to livestream the event on Instagram for guests unable to attend.
Media outlets, psychedelic science enthusiasts and curious members of the public alike are all encouraged to join Optimi Health in celebrating this important milestone.
Psychedelics continue to capture the imagination of people looking for hope and better quality of life, specifically those suffering with debilitating mental health conditions, said Optimi Health CEO, Bill Ciprick.
By having the largest GMP-grade Health Canada licensed mushroom cultivation facility in Canada, we have positioned Optimi to be the number one supplier of safe, natural psilocybin, and we feel good about setting the safest and most stringent production standards in the industry.

Optimi Health Begins Cultivation Of Natural Psilocybin For Use In Clinical Trials

Retrieved on:

Friday, March 18, 2022

VANCOUVER, British Columbia, March 18, 2022 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (Optimi or the Company), is pleased to announce that it has commenced the cultivation of natural GMP-grade psilocybin mushrooms at its Princeton, British Columbia facility.

Key Points:

VANCOUVER, British Columbia, March 18, 2022 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (Optimi or the Company), is pleased to announce that it has commenced the cultivation of natural GMP-grade psilocybin mushrooms at its Princeton, British Columbia facility.
These mushrooms are an important milestone in Optimis commitment to establishing a supply of safe, natural psilocybin products for use by approved parties engaged in clinical trials, said Optimi Health CEO Bill Ciprick.
The initial batch of Optimis natural psilocybin mushrooms is intended specifically for analysis and use in human clinical trials where market demand for natural psilocybin is increasing.
Optimi Executive Chairman, JJ Wilson, adds that todays announcement is a momentum building milestone that speaks to the Companys goal of becoming a world supplier in the cultivation and formulation of natural psilocybin.